Given a higher objective response rate of anti-PD-1 and anti-CTLA-4 in PD-L1 positive lung cancer, it is reasonable to consider adding anti-PD-1 and/or anti-PD-L1 antibodies to the treatment of ALK+ lung cancer, particularly at the time of resistance to ALK inhibitor monotherapy. Here, ALK is linked to lung cancer.